Gilead Sciences - 2/11

Entry	Author	Date	Location
Pharma-Academic Alliances: What the Numbers Don’t Tell You	Stewart Lyman	05/10/11	Seattle
Gilead Cuts Deal With MicroDose	Luke Timmerman	04/20/11	San Francisco
Gilead Drug Fails AIDS Prevention Trial	Luke Timmerman	04/18/11	San Francisco
Gilead Antes Up for Cancer, Genentech Eye Drug Passes Big Trial, Bigger Isn’t Better, & More Bay Area Life Sciences News	Luke Timmerman	04/01/11	San Francisco
Editor’s Picks: Xconomy Seattle’s Top Stories of the First Quarter	Luke Timmerman	03/31/11	Seattle
Gilead Inks $100M Deal With Yale	Luke Timmerman	03/31/11	San Francisco
Doxo, Kashless, Physiosonic led WA’s Equity Financing Deals in February	Curt Woodward	03/21/11	Seattle
Gilead Bets $600M on Cancer, Genentech Gets a Hearing, Jennerex Shows Early Survival Edge, & More Bay Area Life Sciences News	Luke Timmerman	02/25/11	San Francisco
Gilead Wagers $600M on Calistoga, Dendreon Scopes New Digs, Physio to Spin Off, & More Seattle-Area Life Sciences News	Luke Timmerman	02/24/11	Seattle
Gilead Pursues Cancer, Inflammation as Next Step To Diversify Beyond HIV	Luke Timmerman	02/23/11	San Francisco
Calistoga Hands the Keys to Gilead, Bets It Can Make Cancer a Chronic Disease Like HIV	Luke Timmerman	02/23/11	Seattle
Montgomery Startup Gets $1M	Luke Timmerman	02/22/11	Seattle
Gilead Buys Calistoga Pharma for $375M, Making Move Into Cancer Drugs	Luke Timmerman	02/22/11	Seattle
Stromedix Chief, After Reloading the Company Treasury, Sets Sight on Trial for Deadly Lung Disease	Ryan McBride	02/07/11	Boston
The State of Seattle Biotech 2011: Xconomy’s Chat With UW Faculty & Students	Luke Timmerman	01/19/11	Seattle
See You at the JP Morgan Healthcare Conference	Luke Timmerman	01/10/11	National
Biogen Idec’s New R&D Boss, Doug Williams, Spurns Corner Office for a Return to Big Science	Luke Timmerman	01/06/11	Boston
Gilead Buys Arresto for $225M	Luke Timmerman	12/20/10	San Francisco
Dendreon’s Plan to Meet Demand, Arch Banks on Ikaria IPO, RF Surgical Leaves No Sponge Behind, & More Seattle-Area Life Sciences News	Luke Timmerman	11/04/10	Seattle
Montgomery Joins Alder Board	Luke Timmerman	11/01/10	Seattle
Geospiza Adds Montgomery to Board	Luke Timmerman	10/19/10	Seattle
Montgomery Says Goodbye Gilead, Kaleetan’s Plan to Be the Next Dendreon, Calypso’s CEO Exit, & More Seattle-Area Life Sciences News	Luke Timmerman	08/12/10	Seattle
Genentech Inks Antibody Deal, Cytokinetics Sticks With Science First, BioMarin Scraps Drug, & More Bay Area Life Sciences News	Luke Timmerman	08/06/10	San Francisco
Gilead’s Lung Drug Ace, Bruce Montgomery, Hits Free Agent Market, Scopes Startup Ideas	Luke Timmerman	08/05/10	Seattle
LS9 Reveals Key Biofuel Genes, Onyx Drug Passes Big Trial, Solazyme Seeks First-Mover Edge, & More Bay Area Life Sciences News	Luke Timmerman	07/30/10	San Francisco
Gilead Borrowing $2.2B	Luke Timmerman	07/26/10	San Francisco
Venrock Raises $350M Fund	Gregory T. Huang	07/06/10	Boston
Exelixis CEO Takes Biogen Gig, What Drives Brook Byers Crazy, The Mission Bay Biotech Cluster, & More Bay Area Life Sciences News	Luke Timmerman	07/02/10	San Francisco
Gilead Buys CGI for Up To $120M	Luke Timmerman	06/25/10	San Francisco
Genentech’s Souped-Up Antibody, Reg Kelly’s Mission, LS9 Nears Moment of Truth & More Bay Area Life Sciences News	Luke Timmerman	06/25/10	San Francisco
Page 2 of 4	« previous page · next page »

Entry

Author

Date

Location

Pharma-Academic Alliances: What the Numbers Don’t Tell You

Stewart Lyman

05/10/11

Seattle

Gilead Cuts Deal With MicroDose

Luke Timmerman

04/20/11

San Francisco